Aerpio Pharmaceuticals Inc (ARPO) is trading up 34.09% at $1.77 per share so far Wednesday. ARPO is up sharp after they announced that they and the US Government, through nonprofit MTEC, have reached an agreement for an investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) in patients with moderate to severe COVID-19. MTEC will provide up to $5.1 mln in funding while ARPO will provide $2.8 mln with “in kind” spending.
Aerpio Pharmaceuticals Inc (ARPO) stock is higher by 156.52% over the last 12 months, and the average rating from Wall Street analysts is a Sell. InvestorsObserver’s proprietary scoring system, gives ARPO stock a score of 73 out of a possible 100.
That score is chiefly influenced by a long-term technical score of 93. ARPO’s score also includes a short-term technical score of 85. The fundamental score for ARPO is 40. In addition to the average rating from Wall Street analysts, ARPO stock has a mean target price of 1.5. This means analysts expect the stock to decline 15.25% over the next 12 months.
What’s Happening with ARPO Stock Today
Aerpio Pharmaceuticals Inc (ARPO) stock is up 34.27% while the S&P 500 is higher by 0.5% as of 9:39 AM on Wednesday, Aug 5. ARPO is higher by $0.45 from the previous closing price of $1.32 on volume of 8,976,332 shares. Over the past year the S&P 500 has risen 15.31% while ARPO is higher by 156.52%. ARPO lost -$0.46 per share in the over the last 12 months.
